adenine has been researched along with Parkinson Disease, Secondary in 2 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Excerpt | Relevance | Reference |
---|---|---|
") proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor." | 3.74 | Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. ( Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Pupyshev, AB | 1 |
Tenditnik, MV | 1 |
Ovsyukova, MV | 1 |
Akopyan, AA | 1 |
Dubrovina, NI | 1 |
Tikhonova, MA | 1 |
Tronci, E | 1 |
Simola, N | 1 |
Borsini, F | 1 |
Schintu, N | 1 |
Frau, L | 1 |
Carminati, P | 1 |
Morelli, M | 1 |
2 other studies available for adenine and Parkinson Disease, Secondary
Article | Year |
---|---|
Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.
Topics: Adenine; Animals; Autophagy; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Transgenic; MTO | 2021 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavi | 2007 |